Registry and health services research studies play an increasingly important role in evaluating new therapies and digital health solutions. They make it possible to represent healthcare reality beyond the framework of clinical trials and thus generate additional evidence.
BioStats GmbH supports you in the conception, statistical planning, and evaluation of such studies and analyses. Real World Data (RWD) from registries, health insurance records, or other healthcare data sources are prepared to provide robust Real World Evidence (RWE).
Challenges such as incomplete data, software errors, or bias are systematically addressed to ensure reliable and transparent results.
Through this work, a solid foundation is created to demonstrate the effectiveness, safety, and benefits of therapies and digital health solutions in routine care and to answer both scientific questions and regulatory as well as health economic requirements.
Your Contact at BioStats
Contact us for a non-binding conversation with Dr. Alexander Krannich personally.
Frequently Asked Questions
How does BioStats GmbH support the planning of clinical studies?
We help you define clear study endpoints, select a suitable study design, and carefully plan the sample size. In this way, we ensure that your study is based on scientifically sound foundations from the very beginning.
What types of studies does BioStats GmbH have experience with?
We support a wide range of study designs, including cross-sectional studies, case-control studies, cohort studies, and randomized controlled trials (RCTs). We also have special expertise in the field of digital health applications (DiGA).
What statistical methods does BioStats GmbH use?
Our team selects the optimal statistical tests and models for your project. This also includes complex procedures such as adjustment for confounders or handling multiple tests. The goal is to achieve valid and reliable results.
What expertise does Dr. Alexander Krannich bring?
Dr. Krannich is a statistician and data scientist with many years of experience in university and industrial research. His main areas of focus include the analysis of drug studies, medical device and DiGA studies, Health Technology Assessments (HTA) and real-world data (RWD/RWE).
© 2025 BioStats GmbH. All rights reserved. | Webdesign von Philipp Kufferath